Biodrugs

Papers
(The TQCC of Biodrugs is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond238
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry128
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor87
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome75
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making75
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery57
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis53
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis50
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design48
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy37
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?37
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202235
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies32
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart32
Acknowledgement to Referees31
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials30
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic30
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy29
CAR-T Cells and the Kidney: Insights from the WHO Safety Database29
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review28
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?28
Progress and Challenges in the Treatment of Fabry Disease28
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data26
Malaria Vaccines: Progress to Date26
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer25
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance24
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?23
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series22
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects22
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review22
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?20
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout20
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience20
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options20
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment19
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects19
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network19
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy18
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study17
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu17
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight17
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis16
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine15
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 15
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics15
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa15
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig14
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review14
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics13
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab13
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database13
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study13
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis12
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis12
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Heal12
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria11
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs11
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies11
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials11
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases11
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression11
0.078980922698975